Skip to main content
. 2021 Mar 9;16(3):e0246244. doi: 10.1371/journal.pone.0246244

Fig 1. EZH2 inhibitor, GSK343, decreased tri-methylation of Histone 3 at Lysine 27.

Fig 1

(A) Immunoblotting revealed EZH2 and H3K27me3 expression in long-term passage neuroblastoma cell lines. Treatment with increasing concentrations of GSK343 for 24 hours led to a decrease in EZH2 expression with increasing doses. Increasing doses of GSK343 decreased tri-methylation of the EZH2 downstream target, Histone 3 at Lysine 27 (H3K27me3). H3 expression was unchanged. (B, C) Similar to long-term passage cell lines, immunoblotting of the human neuroblastoma PDXs demonstrated a decrease in EZH2 expression with the inhibitor GSK343 as well as a decrease in tri-methylation of Histone 3 at Lysine 27, but H3 was not significantly changed.